The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Open accessAbstract
BACKGROUND: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials. METHODS: Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy. RESULTS: In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression, and 85.9% with exemestane plus ovarian suppression (P=0.009 for tamoxifen alone vs. tamoxifen plus ovarian suppression). The 8-year rate of overall survival was 91.5% with tamoxifen alone, 93.3% with tamoxifen plus ovarian suppression, and 92.1% with exemestane plus ovarian suppression (P=0.01 for tamoxifen alone vs. tamoxifen plus ovarian suppression); among the women who remained premenopausal after chemotherapy, the rates were 85.1%, 89.4%, and 87.2%, respectively. Among the women with cancers that were negative for HER2 who received chemotherapy, the 8-year rate of distant recurrence with exemestane plus ovarian suppression was lower than the rate with tamoxifen plus ovarian suppression (by 7.0 percentage points in SOFT and by 5.0 percentage points in TEXT). Grade 3 or higher adverse events were reported in 24.6% of the tamoxifen-alone group, 31.0% of the tamoxifen-ovarian suppression group, and 32.3% of the exemestane-ovarian suppression group. CONCLUSIONS: Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. The frequency of adverse events was higher in the two groups that received ovarian suppression than in the tamoxifen-alone group. (Funded by Pfizer and others; SOFT and TEXT ClinicalTrials.gov numbers, NCT00066690 and NCT00066703 , respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Self-citation20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Self-citationAdjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Self-citationSurvival patterns after oophorectomy in premenopausal women: a population-based cohort study
Rocca, W. A., Grossardt, B. R., de Andrade, M., Malkasian, G. D., & Melton, L. J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70869-5 · Cited by 547
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., & Manson, J. E. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182864350 · Cited by 454
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Self-citationHarbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Self-citation
Metadata
- Authors
- Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., Climent, M. A., Pavesi, L., Ruhstaller, T., Davidson, N. E., Coleman, R., Debled, M., Buchholz, S., Ingle, J. N., Winer, E. P., Maibach, R., Rabaglio-Poretti, M., Ruepp, B., Di Leo, A., Coates, A. S., Gelber, R. D., Goldhirsch, A., & Regan, M. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-07-12
- Volume
- 379
- Issue
- 2
- Pages
- 122-137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2806866264
- Cited by
- 684
- References
- 23
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. https://app.cochat.ai/papers/10.1056/nejmoa1803164
- The paper
- Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., . . . Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1803164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.